Salute e Benessere

dsm-firmenich reports full year 2023 results

2023 highlights 2023 highlights Dimitri de Vreeze, CEO, commented:"We are proud that the company is already operating seamlessly with integration well ahead of plan, including the development of a common culture, as demonstrated in our recent employee engagement survey. Our employees have done a truly amazing job building momentum, positioning dsm-firmenich as a world leader in nutrition, health and beauty. In light of the unprecedented conditions with very low vitamin prices...

Fagron delivers strong performance with 12% topline growth and 14% increase in…

Regulated information – inside information Nazareth (Belgium)/Rotterdam (The Netherlands), 15 February 2024 – 7AM CET Fagron delivers strong performance with 12% topline growth and 14% increase in REBITDA for FY 2023 Fagron, the leading global player in pharmaceutical compounding today publishes its full year results for the period ending 31 December 2023. Key Highlights Strong topline performance with 11.6% reported revenue growth (12.5% at CER) and 10.5% organic revenue growth...

Valneva Reports Full Year 2023 Revenue and Cash, Provides First 2024 Guidance

Valneva Reports Full Year 2023 Revenue and Cash,Provides First 2024 GuidanceTotal revenues of €153.7 million, including product sales of €144.6 millionProduct sales surpassed pre-pandemic (2019) sales by 12% and 2022 sales by 26%Excluding COVID-19 vaccine sales, product sales grew by 63% compared to 2022Cash position of €126.1 million at December 31, 2023Excludes recent sale of the Priority Review Voucher (PRV) for $103 million (€95 million) 1...

CARBIOS and De Smet Engineers & Contractors enter engineering partnership for…

CARBIOS and De Smet Engineers & Contractors enter engineering partnership for construction of world's first PET biorecycling plantClermont-Ferrand, France, 15 February 2024 (06.45am CET)CARBIOS (Euronext Growth Paris: ALCRB), a pioneer in the development and industrialization of biological technologies to reinvent the life cycle of plastic and textiles, andDe Smet Engineers & Contractors (DSEC), a world-class provider of Engineering, Procurement and Construction services...

Jazz Pharmaceuticals to Report 2023 Full Year and Fourth Quarter Financial…

Interested parties may access the live audio webcast via the Investors section of the Jazz Pharmaceuticals website at https://investor.jazzpharma.com/investors/events-presentations. To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast. Interested parties may access the live audio webcast via the Investors section of the Jazz Pharmaceuticals website athttps://investor.jazzpharma.com/investors/events-presentations...

Consumers' Quest for Wellness Drives Expansion of Global Functional Milk…

Browse in-depth TOC on the Functional Milk Market Browse in-depth TOC on the Functional Milk Market 317 – Pages 120 - Tables 123- Figures Functional Milk Market Report Scope • Vendors Focus on Product Innovation The food and beverage industry is witnessing a notable surge in health consciousness among consumers, driving a preference for nutritional-rich products. This trend has significantly influenced the market, particularly in the demand...

EssilorLuxottica Board of Directors proposes nominees to the new Board

EssilorLuxottica Board of Directors proposes nominees to the new BoardCharenton-le-Pont, France (February 14, 2024 – 6:00pm)– During its meeting today, EssilorLuxottica Board of Directors decided to propose the re-appointment of all current Directors to the next Annual General Meeting to be held on April 30, 2024.To ensure continuity of the Board of Directors' work in the future, it is proposed to progressively implement a staggering of the Directors' terms of office and to appoint as...

EssilorLuxottica Q4/FY 2023 Results - 2023: another record year for…

Q4/FY 2023 RESULTS2023: another record year for EssilorLuxottica Group revenue at constant exchange rates 1+7.1% in Q4 and FY, third consecutive year >7%Nice acceleration in North America in Q4, EMEA keeping the sound pace of Q3Innovation as a key driver, with Stellest, Varilux XR and Ray-Ban MetaFrame portfolio strengthened with new brands, licenses growing double digitsNuance Audio disruptive innovation successfully presented at the CES in Las Vegas...

Hyloris Enrolls First Patient in Phase 3 Clinical Trial for its Proprietary…

Innovative oral care solution aims to benefit patients taking blood thinning medications, who have an increased risk of prolonged bleeding during and after dental procedures Approximately 280 patients in the EU and U.S. will be randomized to receive either tranexamic acid oral solution or placeboLast patient out expected around end of 2024Study results expected first half of 2025Liège, Belgium – February, 14 2024 – 6PM CET – Non-regulated information - Hyloris Pharmaceuticals SA...

Genmab Announces Initiation of Share Buy-Back Program

Company Announcement Repurchase of up to 190,000 shares Honoring commitments under our Restricted Stock Unit program Completion expected on March 15, 2024 COPENHAGEN, Denmark; February 14, 2024 – Genmab A/S (Nasdaq: GMAB) announced today that it is initiating a share buy-back program to honor our commitments under our Restricted Stock Unit program. The share buy-back program will be undertaken on the terms set out below and in accordance with Regulation (EU) No...

Genmab Publishes 2023 Annual Report

Company Announcement COPENHAGEN, Denmark; February 14, 2024 –Genmab A/S (Nasdaq: GMAB) announced today the publication of its Annual Report for 2023.Below is a summary of business progress in 2023, financial performance for the year and the financial outlook for 2024. The full report is attached as a PDF file and in iXBRL format and can be found in the investor section of the company's website, www.genmab.com/investors . Conference CallGenmab will hold a conference call in...

Pharmacogenomics Market Worth $5.8 Billion | MarketsandMarkets™

Browse in-depth TOC on "Pharmacogenomics Market" 369 - Tables 56 - Figures 396 - Pages Browse in-depth TOC on "Pharmacogenomics Market"369 - Tables56 - Figures396 - Pages Pharmacogenomics Market Scope: The kits & reagents segment accounted for the largest share by product & service in the pharmacogenomics market in 2022. By product & service, the pharmacogenomics market has been further categorized kits & reagents and service. Kits & reagents...

Statement of Renovaro Inc

We felt compelled to comment on the shorter Hindenburg's opinion piece.The one thing Hindenburg got right is that the Board of the Company has remained steadfast in their confidence and support in the lifesaving potential of Renovaro. In fact, four exceptional leaders in the field of technology and business have recently joined the Board.The rest of the diatribe is largely rehashed material they have been using in a transparent attempt to make money as an active shorter of the Company's...

UroMems Announces Results of First-Ever Smart Artificial Urinary Sphincter…

"On behalf of the medical team who implanted the UroActive System in the first female patient, Drs. Christophe Vaessen, Aurelien Beaugerie and I are over the moon to see our first patient has returned to living life fully after years of struggling with SUI," said Professor Emmanuel Chartier-Kastler. "This promising therapy is a breakthrough technology in treating SUI in both women and men." "On behalf of the medical team who implanted the UroActive System in the first…

Blue Matter Further Expands Analytics Team, Opens New Office in Gurugram, India

Prasanna added that the global footprint will significantly drive the team's mission to deliver meaningful insights at scale to address a range of commercial business questions that clients regularly face. The team is engaged in a wide range of projects across multiple geographies, most often in complex markets such as oncology (including cell and gene therapies) and rare diseases. Prasanna added that the global footprint will significantly drive the team's mission to deliver meaningful...

Revieve® and Debenhams Redefine UK Beauty Standards with Groundbreaking AI and…

This innovative consultation experience will be rolled out in two phases. The initial phase introduces the Digital Skincare Advisor, offering customers personalised skincare recommendations to empower better-informed decision-making. Explore the experience here: https://www.debenhams.com/categories/beauty-skin-care. This innovative consultation experience will be rolled out in two phases. The initial phase introduces the Digital Skincare Advisor, offering customers personalised skincare...

AIM ImmunoTech Announces First Subject Dosed in the Netherlands for Phase 1b/2…

Phase 1b portion of the study expected to be completed within six months AIM ImmunoTech Inc.(NYSE American: AIM) (“AIM” or the “Company”) today announced the first subject has been dosed at Erasmus Medical Center (“Erasmus MC”) in a Phase 1b/2 clinical trial combining AIM's Ampligen® (rintatolimod) with AstraZeneca's anti-PD-L1 immune checkpoint inhibitor Imfinzi® (durvalumab) for the treatment of late-stage pancreatic cancer (the “DURIPANC Study”). The DURIPANC Study is an...

Enable Injections Announces Plans to Expand Manufacturing Facilities and…

CINCINNATI, Feb. 14, 2024 /PRNewswire/ -- Enable Injections, Inc. ("Enable"), a leading innovator in developing and manufacturing the enFuse® platform of wearable technology, today announced it plans to expand manufacturing operations with a new large-scale facility in Springdale, Ohio as well as enhance the Company's corporate headquarters in Evendale, Ohio. CINCINNATI,Feb. 14, 2024/PRNewswire/ -- Enable Injections, Inc. ("Enable"), a leading innovator in developing and…

Essence SmartCare Selected to Provide Advanced Remote Senior Care Technology for…

Recent reports indicate that Germany's aging population will increase 37% by 2055, from roughly 5.0 million to 6.8 million individuals. Concurrent with this shift in demographics is a growing preference among seniors to live independently at home, putting strain on family members, caretakers, and even emergency responders. This collaborative effort underscores the viability and necessity of advanced telecare solutions, positioning Essence SmartCare at the forefront of a fundamental shift in care…

Avicenna.AI and Blackford Partner to enhance incidental pulmonary embolism…

Incidental pulmonary embolism is a common finding in routine CT scans of the chest, with only 25% of incidental emboli reported during the initial interpretation. Addressing the serious issue of delayed and missed findings in diagnostic imaging, this partnership aims to significantly impact patient outcomes, particularly in the cancer patient population where incidental pulmonary embolism is a major cause of mortality. Incidental pulmonary embolism is a common finding in routine CT scans of…

Carrick Therapeutics Announces First Patient Dosed in Phase 1b/2 Clinical Trial…

/2 clinical trial evaluating the combination of samuraciclib (CT7001), an investigational oral and first-in-class inhibitor of CDK7, and vepdegestrant (ARV-471), an investigational oral PROTAC® (PROteolysis TArgeting Chimera) estrogen receptor (ER) degrader, being jointly developed by Arvinas (Nasdaq: ARVN) and Pfizer (NYSE: PFE) in women with ER+, HER2- metastatic breast cancer who have previously received a CDK4/6 inhibitor. “We're excited to expand clinical development of samuraciclib...

Boehringer Ingelheim Partners with Veeva to Advance its Clinical and Regulatory…

"Veeva Vault Clinical and Veeva Vault RIM will help us drive higher operational efficiency across functions while providing the insights for data-driven decision making," said Marcus Gravendyck, head of global regulatory affairs and pharmacovigilance, Animal Health at Boehringer Ingelheim. "This will allow us to execute and innovate faster to improve the lives of animals." "Veeva Vault Clinical and Veeva Vault RIM will help us drive higher operational efficiency across…

Oncolytics Biotech® Initiates Enrollment Expansion of GOBLET Anal Cancer Cohort

"These exciting clinical data, which exceed the Simon two-stage success criteria, provide strong support to expand the evaluation of pelareorep in patients with advanced anal cancer. The results reported at IMACC 2023 showed that the combination of pelareorep and atezolizumab provided a 37.5% objective response rate, including one patient with a long-lasting complete response, and good overall tolerability. These data represent a meaningful contrast to recent clinical trial results which…

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives…

Bagsværd, Denmark, 14 February 2024— This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company's board members, executives and their associated persons have reported the transactions to Novo Nordisk and have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk...

Altri Comunicati